FDA Finds More Impurities in Novartis Drug Valsartan

See Juston Kunde’s Newsline article on recent FDA inspections identifying yet another carcinogen in some batches of Novartis’ valsartan medicine—medicine for treating coronary heart prerequisites and hypertension.